Kezar Life Sciences, Inc.
KZR
$3.96
-$0.04-1.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.95% | -1.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.19% | -18.29% | |||
| Operating Income | 17.19% | 18.29% | |||
| Income Before Tax | 17.23% | 18.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.23% | 18.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.23% | 18.11% | |||
| EBIT | 17.19% | 18.29% | |||
| EBITDA | 17.39% | 18.47% | |||
| EPS Basic | 17.29% | 59.09% | |||
| Normalized Basic EPS | 17.29% | 59.11% | |||
| EPS Diluted | 17.29% | 59.09% | |||
| Normalized Diluted EPS | 17.29% | 59.11% | |||
| Average Basic Shares Outstanding | 0.07% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||